Gastroenterology and Hepatology Unit, Bonsucesso Federal Hospital, (Ministry of Health), Avenida Londres 616 (21041-030), 3rd Floor, Bonsucesso, Rio de Janeiro, Brazil.
School of Medicine, Estácio de Sá University, Rio de Janeiro, Brazil.
Dig Dis Sci. 2021 Dec;66(12):4525-4535. doi: 10.1007/s10620-020-06791-5. Epub 2021 Jan 3.
Patients with decompensated cirrhosis are at increased risk of mortality, even in absence of ACLF. The CLIF-C AD score (CLIF-C ADs) was proposed as a prognostic score but lacks sufficient validation. Our aim was to describe clinical characteristics and hospital evolution according to score groups and evaluate prognostic capability of CLIF-C ADs alone or in combination with other scores.
Two hundred and sixty-six patients (55 ± 14 years, ascites in 63%, MELD 14 ± 5) were included, and classified as high, intermediate and low CLIF-C ADs in 13, 60 and 27% of cases. Development of new complications of cirrhosis during hospitalization and survival at 3 months were evaluated.
Patients with high CLIF-C ADs had more severe systemic inflammation parameters and higher frequency of organ dysfunction. CLIF-C ADs ≥ 60, when compared to intermediate and low groups, was associated with higher incidence of complications of cirrhosis (90% vs 70% and 49%, p < 0.001) and lower survival (93%, 80% and 50%, p < 0.0001). In multivariate analysis, CLIF-C ADs, ascites and MELD were predictors of survival [(AUROC 0.76 (95% CI 0.69-0.83)]. Absence of ascites or MELD < 14 identified patients with intermediate CLIF-C ADs and good survival (89 and 84%, respectively).
CLIF-C ADs predicts survival in cirrhotic patients with AD. High CLIF-C ADs is associated with higher frequency of organ dysfunction, increased risk of new complications of cirrhosis and high short-term mortality. On the contrary, individuals with low CLIF-C ADs, as well as those with intermediate score without ascites or with low MELD have excellent prognoses.
代偿失调性肝硬化患者的死亡率较高,即使不存在 ACLF 也是如此。CLIF-C AD 评分(CLIF-C ADs)被提议作为一种预后评分,但缺乏充分的验证。我们的目的是根据评分组描述临床特征和住院演变,并评估 CLIF-C ADs 单独或与其他评分联合的预后能力。
共纳入 266 例患者(55±14 岁,腹水 63%,MELD 14±5),根据 CLIF-C ADs 将患者分为高、中、低三组,分别占 13%、60%和 27%。评估住院期间新发生的肝硬化并发症和 3 个月时的生存率。
CLIF-C ADs 较高的患者全身炎症参数更严重,器官功能障碍的发生率更高。与中、低分组相比,CLIF-C ADs≥60 与肝硬化并发症的发生率(90%比 70%和 49%,p<0.001)和生存率(93%、80%和 50%,p<0.0001)较低相关。多变量分析显示,CLIF-C ADs、腹水和 MELD 是生存率的预测因素[AUROC 为 0.76(95%CI 为 0.69-0.83)]。无腹水或 MELD<14 可识别出具有中等 CLIF-C ADs 和良好生存率的患者(分别为 89%和 84%)。
CLIF-C ADs 预测肝硬化失代偿患者的生存率。CLIF-C ADs 较高与器官功能障碍发生率较高、新发生肝硬化并发症风险增加和短期死亡率较高相关。相反,CLIF-C ADs 较低的个体以及无腹水或 MELD 较低的中等评分个体具有极好的预后。